Edgewise Therapeutics Competitors

Edgewise Therapeutics (NASDAQ:EWTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Abcam, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Abcam has a consensus target price of $22.00, indicating a potential upside of 3.48%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Abcam.

Profitability

This table compares Edgewise Therapeutics and Abcam's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Edgewise Therapeutics and Abcam's revenue, earnings per share and valuation.

Summary

Edgewise Therapeutics beats Abcam on 2 of the 2 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Recursion Pharmaceuticals, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Edgewise Therapeutics is more favorable than Recursion Pharmaceuticals.

Profitability

This table compares Edgewise Therapeutics and Recursion Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Edgewise Therapeutics and Recursion Pharmaceuticals' revenue, earnings per share and valuation.

Summary

Edgewise Therapeutics beats Recursion Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Sana Biotechnology has a consensus target price of $40.00, indicating a potential upside of 120.14%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Edgewise Therapeutics and Sana Biotechnology's revenue, earnings per share and valuation.

Summary

Edgewise Therapeutics beats Sana Biotechnology on 2 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Seer, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Seer has a consensus target price of $68.00, indicating a potential upside of 78.57%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Seer's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Edgewise Therapeutics and Seer's revenue, earnings per share and valuation.

Summary

Edgewise Therapeutics beats Seer on 2 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Edgewise Therapeutics and Nuvation Bio, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. Nuvation Bio has a consensus target price of $17.40, indicating a potential upside of 74.00%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts clearly believe Nuvation Bio is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Edgewise Therapeutics and Nuvation Bio's revenue, earnings per share and valuation.

Summary

Nuvation Bio beats Edgewise Therapeutics on 3 of the 3 factors compared between the two stocks.

Edgewise Therapeutics (NASDAQ:EWTX) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings for Edgewise Therapeutics and ImmunityBio, as provided by MarketBeat.

Edgewise Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 17.13%. ImmunityBio has a consensus target price of $25.00, indicating a potential upside of 49.34%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Edgewise Therapeutics.

Profitability

This table compares Edgewise Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Edgewise Therapeutics and ImmunityBio's top-line revenue, earnings per share (EPS) and valuation.

Summary

ImmunityBio beats Edgewise Therapeutics on 2 of the 3 factors compared between the two stocks.